Ivabradine is an effective antiarrhythmic therapy for congenital junctional ectopic tachycardia‐induced cardiomyopathy during infancy: Case studies

• DOI: 10.1111/pace.13402
• Publication Date: 2018-06-01T10:04:28Z
• Authors: Yakup Ergul; Erkut Ozturk; Senem Ozgur; Abdullah Ozyurt; Erman Cilsal; Alper Guzeltas
• Keywords: Ivabradine; Flecainide

Junctional ectopic tachycardia (JET) is a rare form of arrhythmia that most commonly seen during infancy. JET continuous and incessant, characterized by persistently high heart rates may result in impaired cardiac function tachycardia-induced cardiomyopathy. Despite the availability multiple antiarrhythmic treatments, including flecainide amiodarone, management generally very difficult. Catheter ablation has risk atrioventricular block it require placement pacemaker. Ivabradine, also known as pacemaker cell inhibitor, new-generation used to treat sinus angina pectoris adult patients. In this article, we present three cases subjects with infantile congenital who were admitted our clinic The age ranged from 52 days 10 months. Although could not be controlled antiarrhythmics, combination amiodarone combined either propranolol or digoxin, they rapidly converted into rhythm an ivabradine treatment 0.1-0.2 mg/kg/day. No other side effects observed treatment, left ventricular functions rhythms improved within 24 hours. These therefore provide hope suitable standard initial for JET. However, additional research needed confirm validity these results circumstances.